DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced the publication of a research paper on two of the Company's antimicrobial compounds: CSA-8 and CSA-13. The paper appeared in the April issue of the Journal of Antimicrobial Agents and Chemotherapy, a peer-reviewed official Journal of the American Society of Microbiology, dedicated to advances in the field of applied microbiology.
